These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29053203)

  • 1. Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.
    Tang T; Abbott S; le Roux CW; Wilson V; Singhal R; Bellary S; Tahrani AA
    Diabetes Obes Metab; 2018 Mar; 20(3):745-748. PubMed ID: 29053203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
    Samuels JM; Niswender KD; Roumie CL; Spann MD; Flynn CR; Ye F; Blankush J; Irlmeier R; Funk LM; Patel MB
    Diabetes Obes Metab; 2024 Sep; 26(9):3906-3913. PubMed ID: 38934217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study.
    Wu T; Wong CKH; Tang EHM; Man KKC; Wong SKH; Au ICH; Tse ETY; Chan EWY; Grieve E; Wu O; Ng EKW; Wong ICK
    Surg Obes Relat Dis; 2022 Jun; 18(6):762-771. PubMed ID: 35300912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
    Angelidi AM; Kokkinos A; Sanoudou D; Connelly MA; Alexandrou A; Mingrone G; Mantzoros CS
    Metabolism; 2023 Jan; 138():155346. PubMed ID: 36375643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.
    Dicker D; Sagy YW; Ramot N; Battat E; Greenland P; Arbel R; Lavie G; Reges O
    JAMA Netw Open; 2024 Jun; 7(6):e2415392. PubMed ID: 38848064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.
    Chen JH; Tang WH; Lee CH
    J Med Case Rep; 2014 Sep; 8():304. PubMed ID: 25213589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure.
    Wolff Sagy Y; Lavie G; Ramot N; Battat E; Arbel R; Reges O; Dicker D
    Nat Med; 2024 Aug; 30(8):2337-2342. PubMed ID: 38749475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
    Jensen AB; Renström F; Aczél S; Folie P; Biraima-Steinemann M; Beuschlein F; Bilz S
    Obes Surg; 2023 Apr; 33(4):1017-1025. PubMed ID: 36765019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.
    Zhu H; Zhou L; Wang Q; Cai Q; Yang F; Jin H; Chen Y; Song Y; Zhang C
    Ann Rheum Dis; 2023 Sep; 82(9):1218-1226. PubMed ID: 37258065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.
    Morissette A; Mulvihill EE
    J Pharm Pharm Sci; 2024; 27():13065. PubMed ID: 38903652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss during medical weight management does not predict weight loss after bariatric surgery: a retrospective cohort study.
    Abbott S; Lawson J; Singhal R; Parretti HM; Tahrani AA
    Surg Obes Relat Dis; 2020 Nov; 16(11):1723-1730. PubMed ID: 32771426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.
    Dash S
    Diabetes Obes Metab; 2024 Sep; 26 Suppl 4():3-15. PubMed ID: 39157881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy on fasting gastrointestinal and pancreatic peptide hormones: A prospective nonrandomized trial.
    Yang J; Gao Z; Williams DB; Wang C; Lee S; Zhou X; Qiu P
    Surg Obes Relat Dis; 2018 Oct; 14(10):1521-1529. PubMed ID: 30449509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.
    Lassen MCH; Johansen ND; Modin D; Catarig AM; Vistisen BK; Amadid H; Zimmermann E; Gislason G; Biering-Sørensen T
    Diabetes Obes Metab; 2024 Nov; 26(11):5239-5250. PubMed ID: 39215626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
    Neeland IJ; Linge J; Birkenfeld AL
    Diabetes Obes Metab; 2024 Sep; 26 Suppl 4():16-27. PubMed ID: 38937282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment.
    Stenberg E; Ottosson J; Cao Y; Sundbom M; Näslund E
    Br J Surg; 2024 Aug; 111(9):. PubMed ID: 39235379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.
    Liu FP; Dong JJ; Yang Q; Xue XZ; Ren ZF; Gan YZ; Liao L
    J Diabetes; 2015 May; 7(3):322-8. PubMed ID: 25047138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.